+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Drug Addiction (Central Nervous System) - Drugs In Development, 2021

  • ID: 5359590
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 258 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Aelis Farma SAS
  • Allaysis LLC
  • Aphios Corp
  • Astraea Therapeutics LLC
  • Camino Pharma LLC
  • Chiromics LLC
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction (Central Nervous System) - Drugs In Development, 2021, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape.

Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Drug Addiction (Central Nervous System) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Drug Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Drug Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 10, 10, 2, 34 and 8 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 12 and 3 molecules, respectively.

Drug Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Drug Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Drug Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Drug Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Drug Addiction (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Drug Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Drug Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aelis Farma SAS
  • Allaysis LLC
  • Aphios Corp
  • Astraea Therapeutics LLC
  • Camino Pharma LLC
  • Chiromics LLC
  • Introduction
  • Drug Addiction - Overview
  • Drug Addiction - Therapeutics Development
  • Drug Addiction - Therapeutics Assessment
  • Drug Addiction - Companies Involved in Therapeutics Development
  • Drug Addiction - Drug Profiles
Drug Addiction - Dormant Projects

Drug Addiction - Discontinued Products
  • Drug Addiction - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Drug Addiction, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Target, 2021 (Contd..1)
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Drug Addiction - Pipeline by Adjuvance Technologies Inc, 2021
  • Drug Addiction - Pipeline by Aelis Farma SAS, 2021
  • Drug Addiction - Pipeline by Aether Therapeutics Inc, 2021
  • Drug Addiction - Pipeline by Allaysis LLC, 2021
  • Drug Addiction - Pipeline by Amygdala Neurosciences Inc, 2021
  • Drug Addiction - Pipeline by Ananda Scientific Inc, 2021
  • Drug Addiction - Pipeline by Aphios Corp, 2021
  • Drug Addiction - Pipeline by Assertio Therapeutics Inc, 2021
  • Drug Addiction - Pipeline by Astraea Therapeutics LLC, 2021
  • Drug Addiction - Pipeline by BioCorRx Inc, 2021
  • Drug Addiction - Pipeline by Camino Pharma LLC, 2021
  • Drug Addiction - Pipeline by Charleston Laboratories Inc, 2021
  • Drug Addiction - Pipeline by Chiesi Farmaceutici SpA, 2021
  • Drug Addiction - Pipeline by Chiromics LLC, 2021
  • Drug Addiction - Pipeline by Clear Scientific LLC, 2021
  • Drug Addiction - Pipeline by Consegna Pharma Inc, 2021
  • Drug Addiction - Pipeline by Curemark LLC, 2021
  • Drug Addiction - Pipeline by D&A Pharma SAS, 2021
  • Drug Addiction - Pipeline by Daya Drug Discoveries Inc, 2021
  • Drug Addiction - Pipeline by DD Therapeutics LLC, 2021
  • Drug Addiction - Pipeline by Denovo Biopharma LLC, 2021
  • Drug Addiction - Pipeline by Elysium Therapeutics Inc, 2021
  • Drug Addiction - Dormant Projects, 2021
  • Drug Addiction - Discontinued Products, 2021
List of Figures
  • Number of Products under Development for Drug Addiction, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021
Note: Product cover images may vary from those shown
  • Adjuvance Technologies Inc
  • Aelis Farma SAS
  • Aether Therapeutics Inc
  • Allaysis LLC
  • Amygdala Neurosciences Inc
  • Ananda Scientific Inc
  • Aphios Corp
  • Assertio Therapeutics Inc
  • Astraea Therapeutics LLC
  • BioCorRx Inc
  • Camino Pharma LLC
  • Charleston Laboratories Inc
  • Chiesi Farmaceutici SpA
  • Chiromics LLC
  • Clear Scientific LLC
  • Consegna Pharma Inc
  • Curemark LLC
  • D&A Pharma SAS
Note: Product cover images may vary from those shown
Adroll
adroll